National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Vedolizumab (Entyvio®) HTA ID: 20029

Vedolizumab (Entyvio®)  for subcutaneous administration is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or an anti-TNFα.

NCPE Assessment Process Complete
Rapid Review Commissioned 16/06/2020
Rapid Review Completed 12/08/2020
Rapid Review Outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vedolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.